MA26801A1 - Complexe pharmaceutique - Google Patents

Complexe pharmaceutique

Info

Publication number
MA26801A1
MA26801A1 MA26450A MA26450A MA26801A1 MA 26801 A1 MA26801 A1 MA 26801A1 MA 26450 A MA26450 A MA 26450A MA 26450 A MA26450 A MA 26450A MA 26801 A1 MA26801 A1 MA 26801A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical complex
pharmaceutical
complex
Prior art date
Application number
MA26450A
Other languages
English (en)
Inventor
Billotte Anne
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA26801A1 publication Critical patent/MA26801A1/fr

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA26450A 1999-06-29 2001-12-24 Complexe pharmaceutique MA26801A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex

Publications (1)

Publication Number Publication Date
MA26801A1 true MA26801A1 (fr) 2004-12-20

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26450A MA26801A1 (fr) 1999-06-29 2001-12-24 Complexe pharmaceutique

Country Status (44)

Country Link
US (2) US6713461B1 (fr)
EP (1) EP1189640B1 (fr)
JP (2) JP4454900B2 (fr)
KR (1) KR20020015067A (fr)
CN (1) CN1198654C (fr)
AP (1) AP2001002369A0 (fr)
AR (1) AR033337A1 (fr)
AT (1) ATE290884T1 (fr)
AU (1) AU770169B2 (fr)
BG (1) BG106151A (fr)
BR (1) BR0011845A (fr)
CA (1) CA2376847C (fr)
CO (1) CO5170494A1 (fr)
CZ (1) CZ20014572A3 (fr)
DE (1) DE60018744T2 (fr)
DZ (1) DZ3320A1 (fr)
EA (1) EA003908B1 (fr)
EC (1) ECSP003551A (fr)
EE (1) EE200100697A (fr)
ES (1) ES2235879T3 (fr)
GB (1) GB9915231D0 (fr)
GE (1) GEP20043377B (fr)
GT (1) GT200000102A (fr)
HR (1) HRP20010951A2 (fr)
HU (1) HUP0201629A3 (fr)
IL (1) IL146341A0 (fr)
IS (1) IS6163A (fr)
MA (1) MA26801A1 (fr)
MX (1) MXPA01013274A (fr)
NO (1) NO20016430L (fr)
NZ (1) NZ515235A (fr)
OA (1) OA11964A (fr)
PA (1) PA8496801A1 (fr)
PE (1) PE20010346A1 (fr)
PL (1) PL352902A1 (fr)
SK (1) SK18932001A3 (fr)
SV (1) SV2002000112A (fr)
TN (1) TNSN00142A1 (fr)
TR (1) TR200103827T2 (fr)
UA (1) UA66932C2 (fr)
UY (1) UY26224A1 (fr)
WO (1) WO2001000243A1 (fr)
YU (1) YU87501A (fr)
ZA (1) ZA200110454B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
GEP20063996B (en) * 2002-08-20 2006-12-11 Bristol Myers Squibb Co Aripiprazole complex formulation and use thereof
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (fr) * 2016-01-15 2017-07-20 Cadila Healthcare Limited Composition intranasale comprenant des agonistes de récepteur 5ht1b/1d
WO2019143925A1 (fr) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Compositions liquides de rizatriptan

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
HU211648A9 (en) 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
PL168919B1 (pl) 1990-10-15 1996-05-31 Pfizer Sposób wytwarzania nowych pochodnych indolu PL PL PL PL
EP0687174B1 (fr) 1993-03-05 2001-06-13 Hexal Ag Complexes cristallins d'insertion de cyclodextrine de l'hydrochlorure de ranitidine, et leur procede de preparation
IL128774A (en) 1994-03-07 2001-05-20 Dow Chemical Co Composition comprising a dendritic poymer in complex with at least one unit of biological response modifier and a process for the preparation thereof
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
IL127956A0 (en) 1996-07-11 1999-11-30 Farmarc Nederland Bv Inclusion complex containing indole selective serotonin agonist
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
JP3350061B2 (ja) 1997-07-03 2002-11-25 ファイザー・インク エレトリプタンヘミスルフェートおよびカフェインを含有する医薬組成物
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
CN1359303A (zh) 2002-07-17
WO2001000243A1 (fr) 2001-01-04
EP1189640B1 (fr) 2005-03-16
HRP20010951A2 (en) 2005-04-30
PL352902A1 (en) 2003-09-22
YU87501A (sh) 2004-05-12
CA2376847A1 (fr) 2001-01-04
CN1198654C (zh) 2005-04-27
GEP20043377B (en) 2004-04-13
UA66932C2 (en) 2004-06-15
AP2001002369A0 (en) 2001-12-31
DE60018744D1 (de) 2005-04-21
JP2006257091A (ja) 2006-09-28
CO5170494A1 (es) 2002-06-27
BG106151A (en) 2002-05-31
IS6163A (is) 2001-11-16
JP4454900B2 (ja) 2010-04-21
DE60018744T2 (de) 2006-05-18
EA003908B1 (ru) 2003-10-30
CA2376847C (fr) 2007-09-25
TNSN00142A1 (fr) 2005-11-10
SK18932001A3 (sk) 2002-09-10
SV2002000112A (es) 2002-02-05
AU770169B2 (en) 2004-02-12
IL146341A0 (en) 2002-07-25
PE20010346A1 (es) 2001-03-26
US20040186076A1 (en) 2004-09-23
UY26224A1 (es) 2001-01-31
EP1189640A1 (fr) 2002-03-27
ATE290884T1 (de) 2005-04-15
ZA200110454B (en) 2002-12-20
KR20020015067A (ko) 2002-02-27
ES2235879T3 (es) 2005-07-16
US6713461B1 (en) 2004-03-30
HUP0201629A3 (en) 2003-11-28
EE200100697A (et) 2003-02-17
NO20016430L (no) 2002-02-26
MXPA01013274A (es) 2002-06-04
PA8496801A1 (es) 2002-02-21
EA200101106A1 (ru) 2002-06-27
CZ20014572A3 (cs) 2002-08-14
TR200103827T2 (tr) 2002-05-21
NZ515235A (en) 2003-08-29
GT200000102A (es) 2001-12-14
DZ3320A1 (fr) 2001-01-04
HUP0201629A2 (hu) 2003-03-28
ECSP003551A (es) 2002-01-25
JP2003503364A (ja) 2003-01-28
AR033337A1 (es) 2003-12-17
OA11964A (en) 2006-04-17
BR0011845A (pt) 2002-03-05
AU4774100A (en) 2001-01-31
GB9915231D0 (en) 1999-09-01
NO20016430D0 (no) 2001-12-28

Similar Documents

Publication Publication Date Title
NO20015175D0 (no) Farmasöytisk sammensetning
DE60040552D1 (de) Medikamentspender
NO20033556D0 (no) Farmasöytiske preparater
DE50002776D1 (de) Fungizide wirkstoffkombinationen
FI991485L (fi) Uusi farmaseuttinen koostumus
DE60011853D1 (de) Injektionsspritze
NO20020304D0 (no) Konserverte farmasöytiske preparater
PT1242087E (pt) Composicoes farmaceuticas
KR20050009999A (ko) 약제학적 제제
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
DE50001455D1 (de) Blisterverpackung
NO20020086D0 (no) Smaksmaskerte farmasöytiske flytende formuleringer
PT1210085E (pt) Solucoes farmaceuticas de levosimendano
NO20022606D0 (no) Farmasöytiske kombinasjoner
DK1275397T3 (da) Lægemiddel til lokal anvendelse
EP1408896A4 (fr) Composition pharmaceutique
NO20014926D0 (no) Farmasöytiske forbindelser
PT1239832E (pt) Composicoes farmaceuticas
DZ3164A1 (fr) Nouvel agent pharmaceutique.
MA26801A1 (fr) Complexe pharmaceutique
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
AR025867A1 (es) Formulacion portasdora farmaceutica
FI4488U1 (fi) Farmaseuttinen koostumus
DE50007895D1 (de) Fungizide wirkstoffkombinationen
DZ3163A1 (fr) Nouvelle substance pharmaceutique.